Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval. The outcome of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results